ADORA2A and COVID-19: Others have reviewed the mechanisms of and hypothesized on the potential therapeutic benefit of using an α2 AR agonist, such as dexmedetomidine (DEX) or clonidine, to mitigate COVID-19 morbidity and mortality (24–26).